Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
Authors:
- Yanjie HaoYHYanjie Hao
- Dylan HansenDHDylan Hansen
- Worawit LouthrenooWLWorawit Louthrenoo
- Yi-Hsing ChenYCYi-Hsing Chen
- Jiacai ChoJCJiacai Cho
- Aisha LateefALAisha Lateef
- Laniyati HamijoyoLHLaniyati Hamijoyo
- Shue-Fen LuoSLShue-Fen Luo
- Yeong-Jian Jan WuYWYeong-Jian Jan Wu
- Sandra NavarraSNSandra Navarra
- Leonid ZamoraLZLeonid Zamora
- Zhanguo LiZLZhanguo Li
Open Access
- 18 September 2024
- journal article
- research article
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001217
Abstract
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity. Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded. Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3–5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007). Conclusions LLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.Keywords
Funding Information
- AstraZeneca, Bristol
- Bristol-Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Janssen Research and Development
- Merck Serono
- UCB
This publication has 34 references indexed in Scilit:
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled TrialArthritis & Rheumatology, 2022
- Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohortClinical Rheumatology, 2021
- Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation studyThe Lancet Rheumatology, 2019
- Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American EthnicityArthritis Care & Research, 2019
- Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus ErythematosusArthritis Care & Research, 2019
- Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus CohortArthritis & Rheumatology, 2018
- Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort studyRheumatology International, 2015
- Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multiple‐Cause‐of‐Death AnalysisArthritis & Rheumatology, 2014
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997